Everads Injector in Suprachoroidal Administration of TA Suspension, for Treatment of Patients With DME - Trial NCT06314217
Access comprehensive clinical trial information for NCT06314217 through Pure Global AI's free database. This phase not specified trial is sponsored by Everads Therapy and is currently Recruiting. The study focuses on Diabetic Macular Edema. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Everads Therapy
Timeline & Enrollment
N/A
Feb 18, 2024
Mar 30, 2025
Primary Outcome
Frequency of treatment-emergent adverse events,Frequency of adverse device effects
Summary
This is an open-label pilot device study. The aim of the study is to evaluate the safety and
 performance of Everads Injector following single injection of suspension approved for ocular
 use into the suprachoroidal space.
 
 The study population is patients diagnosed with diabetic macular edema (DME) that were
 previously treated. 10 adult subjects are expected to be enrolled based on the
 inclusion-exclusion criteria.
 
 The study will involve 6 visits during a period of 6 weeks
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06314217
Device Trial